Literature DB >> 8392561

Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors.

B A Fuchs1, S B Pruett.   

Abstract

We tested the hypothesis that the previously observed loss of thymic lymphocytes in mice after treatment with time-release morphine pellets was occurring through the process of apoptosis. Apoptosis is a form of cell death, distinct from necrosis, which involves a specific endonuclease that fragments the cell's own DNA. Forty-eight hours after implantation of a time-release morphine pellet in B6C3F1 mice, thymus weight and cellularity was reduced to 30% of that observed in placebo-treated mice. Thymocytes from morphine pellet-treated mice were found to have a significantly greater percentage of their DNA fragmented than did thymocytes from either placebo pellet-implanted or naive control mice. The peak level of DNA fragmentation was found to occur approximately 12 hr postpellet implant. When separated on agarose gels, the sizes of the DNA fragments observed corresponded to the multiples of 180 base pairs which are characteristic of apoptosis. In vivo, the use of either the opiate receptor antagonist naloxone, or the glucocorticoid receptor antagonist RU-38486, was able to block completely the morphine mediated increase in thymocyte apoptosis. In vitro experiments in which thymocytes were cultured with morphine concentrations as high as 10(-4) M showed no evidence of an increased rate of DNA fragmentation. These data indicate that both opiate and glucocorticoid receptors are involved in morphine-induced apoptosis and that the opiate receptor responsible is not located on the thymic lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392561

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene.

Authors:  C Gavériaux-Ruff; H W Matthes; J Peluso; B L Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 3.  Effects of opioids on the immune system.

Authors:  S Roy; H H Loh
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  Induction of apoptotic cell death in rat thymus and spleen after a bolus injection of methamphetamine.

Authors:  M Iwasa; Y Maeno; H Inoue; H Koyama; R Matoba
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

5.  Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Authors:  Elizabeth M Podhaizer; Shiping Zou; Sylvia Fitting; Kimberly L Samano; Nazira El-Hage; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-19       Impact factor: 4.147

Review 6.  Corticosteroid receptor antagonists: a current perspective.

Authors:  W Sutanto; E R de Kloet
Journal:  Pharm World Sci       Date:  1995-03-24

7.  Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B.

Authors:  P C Singhal; K Reddy; N Franki; V Sanwal; N Gibbons
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

Review 8.  Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias.

Authors:  T N James
Journal:  Trans Am Clin Climatol Assoc       Date:  1994

9.  Regulation of mu opioid receptor expression in developing T cells.

Authors:  Lily Zhang; Judith Sliker Belkowski; Tammi Briscoe; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-25       Impact factor: 4.147

10.  Evidence for the nucleus accumbens as a neural substrate of heroin-induced immune alterations.

Authors:  Timothy B Saurer; Stephanie G Ijames; Donald T Lysle
Journal:  J Pharmacol Exp Ther       Date:  2009-03-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.